OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Clinical Dermatology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Cutaneous Manifestations of COVID-19: An Evidence-Based Review	109
The Skin Microbiome: A New Actor in Inflammatory Acne	108
Skin Microbiota and its Interplay with Wound Healing	92
Sunscreens and Photoaging: A Review of Current Literature	84
Rosacea: New Concepts in Classification and Treatment	78
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review	76
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis	70
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib	66
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study	63
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program	62
Psychosocial Effects of Vitiligo: A Systematic Literature Review	60
Effects of Diet on Acne and Its Response to Treatment	58
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	57
New and Emerging Targeted Therapies for Vascular Malformations	55
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)	54
Dermatitis Herpetiformis: An Update on Diagnosis and Management	53
Skin Microbiome and its Interplay with the Environment	52
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review	52
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis	52
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic	51
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm	50
Clinical Course and Characteristics of Generalized Pustular Psoriasis	49
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors	47
Pathophysiology of Generalized Pustular Psoriasis	44
A Review of Noninvasive Techniques for Skin Cancer Detection in Dermatology	43

Ceramides in Skin Health and Disease: An Update	42
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses	41
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study	38
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options	37
Skin Microbiome as Years Go By	35
New Practical Aspects of Sweet Syndrome	33
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies	33
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis	32
Deucravacitinib for the Treatment of Psoriatic Disease	32
Teledermatology During COVID-19: An Updated Review	32